IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bakker et al

Serial No.: 10/517,941

Filed: December 13, 2004

For: AGONISTIC BINDING MOLECULES

TO THE HUMAN OX40 RECEPTOR

Confirmation No.: To be assigned

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2578-6723US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 27, 2005

е

Aubry Blackburn

Name (Type/Print)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of U.S. patents are <u>not</u> being submitted pursuant to M.P.E.P. 609 III A(2). Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2)

Serial No.: 10/517,941

U.S. Patent Documents

U.S. Patent No.	Publication Date	<u>Patentee</u>
US - 5,696,100	12-09-1997	Holme et al.
US - 6,265,150	07-24-2001	Terstappen et al.
US - 6,312,700	11-06-2001	Weinberg
US - 2001/0044522	11-22-2001	Godfrey et al.
US - 5,821,332	10-13-1998	Godfrey et al.
US - 6,277,962	08-21-2001	Godfrey et al.

Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>
WO 98/15833	04-16-1998	Universiteit Utrecht
WO 99/42585	08-26-1999	Sisters of Providence in
		Oregon
WO 95/12673	12-24-2003	Crucell Holland B.V.
WO 03/106498	12-24-2003	Crucell Holland B.V.

Other Documents

- PCT International Search Report, PCT/EP2003/106498, dated January 7, 2004.
- PCT International Preliminary Examination Report, PCT/EP2003/106498, dated July 21, 2004.
- VAUGHAN et al., "Human antibodies by design," Nature Biotechnology, June 1998, pp. 535-539, vol. 16.
- WEINBERG et al., "Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity," Journal of Immunology, 15 February 2000, pp. 2160-2169, vol. 164, no. 4.
- WEINBERG, A., "OX40: targeted immunotherapy implications for tempering autoimmunity and enhancing vaccines," Trends in Immunology, February 2002, pp. 102-109, vol. 23, no. 2.

Serial No.: 10/517,941

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

G. Scott Dorland, Ph.D. Registration No. 51,622 Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: June 24, 2005

GSD/alb

Enclosures: Form PTO/SB/08

Cited Documents

Document in ProLaw

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/517,941	
				Filing Date	December 13, 2004	
STATEMENT DI ATTEICANT		First Named Inventor	Bakker et al			
				Group Art Unit	To be assigned	
	(use as many shee	ets as	necessary)	Examiner Name	To be assigned	
Sheet	1	of	2	Attorney Docket Number	2578-6723US	

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials *	No.	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
		US-5,696,100	12-09-1997	Holme et al.	
		US- 6,265,150	07-24-2001	Terstappen et al.	
		US- 6,312,700	11-06-2001	Weinberg	
		US- 2001/0044522	11-22-2001	Godfrey et al.	
		US- 5,821,332	10-13-1998	Godfrey et al.	
		US- 6,277,962	08-21-2001	Godfrey et al.	
		US-			

Examiner	Cite	Foreign Patent Document]	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 98/15833	04-16-1998	Universiteit Utrecht		
		WO 99/42585	08-26-1999	Sisters of Providence in Oregon		
		WO 95/12673	12-24-2003	Crucell Holland B.V.		
		WO 03/106498	12-24-2003	Crucell Holland B.V.		
	-					

Examiner Signature	Date Considered	_

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Subst	itute for form 1449A	/РТО			Complete if Known	
				Application Number	10/517,941	 _
			ISCLOSURE	Filing Date	December 13, 2004	
ST	STATEMENT BY APPLICANT		First Named Inventor	Bakker et al		
				Group Art Unit	To be assigned	
	(use as ma	any sheets as	necessary)	Examiner Name	To be assigned	
She	et 2	of	2	Attorney Docket Number	2578-6723US	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		PCT International Search Report, PCT/EP2003/106498, dated January 7, 2004.			
		PCT International Search Report, PCT/EP2003/106498, dated January 7, 2004.			
		VAUGHAN et al., "Human antibodies by design," Nature Biotechnology, June 1998, pp. 535-539, vol. 16.			
		WEINBERG et al., "Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity," Journal of Immunology, 15 February 2000, pp. 2160-2169, vol. 164, no. 4.			
		WEINBERG, A., "OX40: targeted immunotherapy - implications for tempering autoimmunity and enhancing vaccines," Trends in Immunology, February 2002, pp. 102-109, vol. 23, no. 2.			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.